Netarsudil (AR-13324) Ophthalmic Solution 0.02%

DRUG3 trials

Sponsors

Aerie Pharmaceuticals

Conditions

Ocular HypertensionOpen Angle GlaucomaOpen-angle Glaucoma

Phase 2

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

CompletedNCT02057575

Aerie PharmaceuticalsOcular Hypertension, Open Angle Glaucoma

Start: 2014-01-31End: 2014-06-30Updated: 2019-06-04

Phase 3

Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

CompletedNCT02558400

Aerie PharmaceuticalsOcular Hypertension, Open-angle Glaucoma

Start: 2015-09-18End: 2017-06-30Updated: 2019-06-04

Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

CompletedNCT02674854

Aerie PharmaceuticalsOcular Hypertension, Open-angle Glaucoma

Start: 2016-02-29End: 2017-03-31Updated: 2019-05-21

Related Papers

Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2

Advances in Therapy2020-03-1284 citations

Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2.

2020-01-2414 citations

Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension

British Journal of Ophthalmology2015-07-24101 citations